Análisis de coste-efectividad en el tratamiento farmacológico del síndrome de fibromialgia en México

  title={An{\'a}lisis de coste-efectividad en el tratamiento farmacol{\'o}gico del s{\'i}ndrome de fibromialgia en M{\'e}xico},
  author={H{\'e}ctor Arreola Ornelas and A. Rosado Buzzo and Lourdes Romero Garc{\'i}a and Javier Dorantes Aguilar and Iris Contreras Hern{\'a}ndez and Joaqu{\'i}n F Mould Quevedo},
  journal={Reumatolog{\'i}a Cl{\'i}nica},
1 Citations
Effectiveness of a structured group intervention based on pain neuroscience education for patients with fibromyalgia in primary care: A multicentre randomized open‐label controlled trial
There has been increased interest in pain neuroscience education (PNE) as a therapeutic approach for the management of fibromyalgia (FM).


Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia
According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain.
Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care
Patients with FM prescribed pregabalin or duloxetine were characterized by a significant comorbidity and pain/adjuvant medication burden, and although healthcare costs increased in both groups, there were no statistically significant differences in direct healthcare costs between the two groups.
Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants
Despite attempts to address bias through PSM, the higher pre-index costs in the pregabalin cohort suggest a channeling of patients with more severe fibromyalgia to preGabalin.
Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective
A decision-analytic model found pregabalin 300 mg and 450’mg to be cost effective compared with placebo and, within the limits of available evidence, against duloxetine using standard UK criteria in patients with fibromyalgia experiencing severe pain.
A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.
The study indicates that MOCLO may not be helpful in FM patients free from clinically meaningful psychiatric problems, but the improvement was invalidated by the poor success of the drug with regard to sleep.
Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States
The results suggest that the introduction of duloxetine into the standard treatment sequence for fibromyalgia not only provides additional patient benefits, reflected by time spent in pain control, but also is cost effective when compared with commonly adopted thresholds.